The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis

Current Medical Research and Opinion

Volumn 21, Issue 7, 2005, Pages 1027-1034

  Genant, Harry K ^a   Halse, Johan ^b   Briney, Walter G ^c   Xie, Li ^d   Glass, Emmett V ^d   Krege, John H ^d  

^a SYNARC INC   (United States)

^b Betanien Medical Center   (Norway)

^c DENVER HEALTH MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Back pain; Osteoporosis treatment; Parathyroid hormone; Postmenopausal; Teriparatide

Indexed keywords

PARATHYROID HORMONE[1-34];

ADULT; AGED; BACKACHE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PAIN ASSESSMENT; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SPINE RADIOGRAPHY; VERTEBRA FRACTURE;

BACK PAIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; SPINAL FRACTURES; TERIPARATIDE; TREATMENT OUTCOME;

EID: 22744454945     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X49671     Document Type: Conference Paper

References (33)

1. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 2000;17:1-45
2. Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128: 793-800
3. Melton III LJ, Lane AW, Cooper C, et al. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993;3:113-9
4. Ettinger B, Black DM, Nevitt MC, et al. Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1992;7:449-56
5. Mazanec DJ, Podichetty VK, Mompoint A, et al. Vertebral compression fractures: manage aggressively to prevent sequelae. Cleve Clin J Med 2003;70:147-56
6. Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheum Dis Clin North Am 2001;27:255-62
7. Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000;15:1384-92
8. Silverman SL, Minshall ME, Shen W, et al. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001;44:2611-9
9. Melton III LJ. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003;18:1139-41
10. Gehlbach SH, Burge RT, Puleo E, et al. Hospital care of osteoporosis-related vertebral fractures. Osteoporos Int 2003;14:53-60
11. Finnern HW, Sykes DP. The hospital cost of vertebral fractures in the EU: estimates using national datasets. Osteoporos Int 2003;14:429-36
12. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
13. Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-48
14. Black DM, Palermo L, Nevitt MC, et al. Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:90-101
15. Pluijm SM, Tromp AM, Smit JH, et al. Consequences of vertebral deformities in older men and women. J Bone Miner Res 2000;15:1564-72
16. Finsen V. Osteoporosis and back pain among the elderly. Acta Med Scand 1988;223:443-9
17. Nakajima A, Shimoji N, Shiomi K, et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 2002;17:2038-47
18. Heaney RP. The natural history of vertebral osteoporosis. Is low bone mass an epiphenomenon? Bone 1992;13(Suppl 2):S23-6
19. Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 2002;13:858-67
20. Chesnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76
21. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
22. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43
23. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
24. Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 2000;160:77-85
25. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35
26. McClung MR, San Martin J, Miller PD, et al. Teriparatide and alendronate increase bone mass by opposite effects on bone remodeling. Arch Intern Med 2005 [in press]
27. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
28. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
29. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
30. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45
31. Cranney A, Tugwell P, Cummings S, et al. Osteoporosis clinical trials endpoints: candidate variables and clinimetric properties. J Rheumatol 1997;24:1222-9
32. Wells G, Cranney A, Shea B, et al. Responsiveness of endpoints in osteoporosis clinical trials. J Rheumatol 1997;24:1230-3
33. OMERACT 3-Workshop report guidelines for osteoporosis trials. J Rheumatol 1997;24:1234-6